Voclosporin

92 interactions 7 explained in plain English

Also sold as: Lupkynis Lupkynis®

About Voclosporin

Voclosporin is used in combination with other mycophenolate mofetil (Cellcept) and corticosteroids like methylprednisolone or prednisone for treatment of lupus nephritis (an autoimmune disease in which the immune system attacks the kidneys) in adults. Voclosporin is in a class of medications called immunosupressants. I… Read the full Voclosporin drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Lefamulin Ketoconazole Topical Oxaliplatin Injection Hydroxychloroquine Atogepant Ivabradine

2 Contraindicated 89 Major 1 Moderate

All (92) Contraindicated (2) Major (89) Moderate (1)

Major

Voclosporin Everolimus Afinitor Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Voclosporin Exemestane Aromasin Increased OATP1B1 substrate exposure Details Voclosporin Famotidine Calmicid An increased risk of QT interval prolongation Details Voclosporin Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Voclosporin Felbamate Felbatol An increased risk of QT interval prolongation Details Voclosporin Fexofenadine Allegra Increased OATP1B1/OATP1B3 substrate exposure Details Voclosporin Flecainide Tambocor® An increased risk of QT interval prolongation Details Voclosporin Fluvastatin Lescol Increased OATP1B1/OATP1B3 substrate exposure Details Voclosporin Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Voclosporin Galantamine Razadyne An increased risk of QT interval prolongation Details Voclosporin Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Voclosporin Gemifloxacin Factive An increased risk of QT interval prolongation Details Voclosporin Glasdegib Daurismo An increased risk of QT interval prolongation Details Voclosporin Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Voclosporin Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Voclosporin Granisetron Injection Granisol An increased risk of QT interval prolongation Details Voclosporin Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Voclosporin Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Voclosporin Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Voclosporin Ivabradine Corlanor An increased risk of QT interval prolongation Details Voclosporin Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Voclosporin Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Voclosporin Lenvatinib Lenvima An increased risk of QT interval prolongation Details Voclosporin Letermovir Injection Prevymis Increased voclosporin exposure, an increased risk of acute and/or chronic nephrotoxicity and an increased letermovir exposure Details Voclosporin Levofloxacin Levaquin An increased risk of QT interval prolongation Details Voclosporin Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Voclosporin Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Voclosporin Lovastatin Altocor® Increased OATP1B1 substrate exposure Details Voclosporin Mefloquine Lariam® An increased risk of QT interval prolongation Details Voclosporin Methotrexate Jylamvo Increased OATP1B1 substrate exposure Details Voclosporin Methotrexate Injection Abitrexate® Increased OATP1B1 substrate exposure Details Voclosporin Metronidazole Flagyl An increased risk of QT interval prolongation Details Voclosporin Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Voclosporin Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Voclosporin Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Voclosporin Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Voclosporin Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Voclosporin Moxifloxacin Avelox An increased risk of QT interval prolongation Details Voclosporin Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Voclosporin Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.